Sausan Moharram (Former)
1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Role of FLT3 in Acute Myeloid Leukemia: Molecular mechanisms and Therapeutic opportunities
2021) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
- 2019
-
Mark
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
(
- Contribution to journal › Letter
-
Mark
Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation
(
- Contribution to journal › Article
- 2018
-
Mark
SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation
(
- Contribution to journal › Article
-
Mark
Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression
(
- Contribution to journal › Letter
- 2017
-
Mark
Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD
(
- Contribution to journal › Article
-
Mark
Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia
(
- Contribution to journal › Article
-
Mark
The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)
(
- Contribution to journal › Article
-
Mark
ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling
(
- Contribution to journal › Article
-
Mark
T-cell acute lymphoblastic leukemia cells display activation of different survival pathways
(
- Contribution to journal › Article